BioSpace News Archive

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced financial results for the full year 2020 and provided a corporate update.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced the publication of two abstracts that will be presented as electronic posters during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the planned presentation of two posters at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021.

The transplant team at Tampa General Hospital performed 611 organ transplants in 2020, eclipsing the hospital’s previous total and making it the sixth busiest transplant center in the nation.

This multi-million-dollar program, with direct application to testing staff and restoring flights departing Toronto Pearson, is funded by the Government of Canada through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.

Apollo Medical Holdings, Inc., a leading physician-centric, technology-powered healthcare management company, announced its consolidated financial results for the fourth quarter and year ended December 31, 2020.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the fourth quarter and full year ended December 31, 2020.

Lenzilumab™ clinical development program for COVID-19 advances from IND to completion of Phase 3 enrollment in fewer than 12 months